@rajivkhanna.bsky.social
Reposted
Andexanet alfa (Andexxa) will officially be taken off the U.S. market this month as an emergency reversal medication for contemporary blood thinners.
https://www.medpagetoday.com/publichealthpolicy/fdageneral/119001
https://www.medpagetoday.com/publichealthpolicy/fdageneral/119001
Anticoagulant Reversal Drug Pulled From U.S. Market
Andexanet alfa (Andexxa) was denied full FDA approval last year
www.medpagetoday.com
December 16, 2025 at 12:11 AM
Andexanet alfa (Andexxa) will officially be taken off the U.S. market this month as an emergency reversal medication for contemporary blood thinners.
https://www.medpagetoday.com/publichealthpolicy/fdageneral/119001
https://www.medpagetoday.com/publichealthpolicy/fdageneral/119001
China Reaffirms Tight Grip on Gold Market, Ushering in a New Monetary Era
open.substack.com/pub/thegoldo...
open.substack.com/pub/thegoldo...
China Reaffirms Tight Grip on Gold Market, Ushering in a New Monetary Era
Without a doubt, the Chinese central bank (PBoC) is still the leading single entity that is driving up the gold price to record highs, year-to-date by more than 55 percent.In the third quarter of 2025...
open.substack.com
December 14, 2025 at 3:03 PM
China Reaffirms Tight Grip on Gold Market, Ushering in a New Monetary Era
open.substack.com/pub/thegoldo...
open.substack.com/pub/thegoldo...
China Reaffirms Tight Grip on Gold Market, Ushering in a New Monetary Era
open.substack.com/pub/thegoldo...
open.substack.com/pub/thegoldo...
China Reaffirms Tight Grip on Gold Market, Ushering in a New Monetary Era
Without a doubt, the Chinese central bank (PBoC) is still the leading single entity that is driving up the gold price to record highs, year-to-date by more than 55 percent.In the third quarter of 2025...
open.substack.com
December 14, 2025 at 1:17 PM
China Reaffirms Tight Grip on Gold Market, Ushering in a New Monetary Era
open.substack.com/pub/thegoldo...
open.substack.com/pub/thegoldo...
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Poo...
PURPOSEPatients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H)
resectable gastroesophageal adenocarcinoma (GEA) have better survival after surgery
and scant/no benefit f...
ascopubs.org
November 16, 2025 at 6:47 PM
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...
Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...
Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match
ascopubs.org
November 16, 2025 at 6:44 PM
Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...
Reposted
Immune Checkpoint Inhibitors Retain Their Role in the HCC Treatment Paradigm @fredhutch.bsky.social #LiverCancer #oncology www.onclive.com/view/immune-...
Immune Checkpoint Inhibitors Retain Their Role in the HCC Treatment Paradigm
Gentry King, MD, highlights the evolution of treatments in the hepatocellular carcinoma landscape and the impact of the phase 3 HIMALAYA trial.
www.onclive.com
February 19, 2025 at 10:40 PM
Immune Checkpoint Inhibitors Retain Their Role in the HCC Treatment Paradigm @fredhutch.bsky.social #LiverCancer #oncology www.onclive.com/view/immune-...
Reposted
Not every place recognizes your value in that moment. Never abandon your dream and surround yourself with supporters. I didn't match for #MedOnc my application year, but now I'm honored to serve #GIonc and #pallonc patients. #MedEd #MedSky #ShareRejection
#medSky #medstudentSky reminder: Failure is part success.
Today I was organizing some papers and found these 3 #rejection letters from medical school from Stanford, Yale, and UCSF.
Normalizing rejection is just as important as sharing your wins. #ShareyourRejection
Today I was organizing some papers and found these 3 #rejection letters from medical school from Stanford, Yale, and UCSF.
Normalizing rejection is just as important as sharing your wins. #ShareyourRejection
July 7, 2025 at 8:19 AM
Reposted
A a high yield #GIonc review of #IO agents in #hpbcsm
#IO has transformed treatment, ⬆️ #OS and creating new #SoC.
💉 Reviews #regimens
🤝 Discusses #synergy with chemo
🚧 Highlight unmet #needs
🔗: cancertreatmentreviews.com/article/S030...
@oncoalert.bsky.social
@weoncologists.bsky.social
#IO has transformed treatment, ⬆️ #OS and creating new #SoC.
💉 Reviews #regimens
🤝 Discusses #synergy with chemo
🚧 Highlight unmet #needs
🔗: cancertreatmentreviews.com/article/S030...
@oncoalert.bsky.social
@weoncologists.bsky.social
The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers
Hepatobiliary malignancies represent a growing global health burden, with rising incidence
rates worldwide [1–3]; however, recent years have witnessed remarkable therapeutic
breakthroughs that are res...
cancertreatmentreviews.com
July 2, 2025 at 12:56 PM
A a high yield #GIonc review of #IO agents in #hpbcsm
#IO has transformed treatment, ⬆️ #OS and creating new #SoC.
💉 Reviews #regimens
🤝 Discusses #synergy with chemo
🚧 Highlight unmet #needs
🔗: cancertreatmentreviews.com/article/S030...
@oncoalert.bsky.social
@weoncologists.bsky.social
#IO has transformed treatment, ⬆️ #OS and creating new #SoC.
💉 Reviews #regimens
🤝 Discusses #synergy with chemo
🚧 Highlight unmet #needs
🔗: cancertreatmentreviews.com/article/S030...
@oncoalert.bsky.social
@weoncologists.bsky.social